Biopharmaceutical Sciences examines the interaction of drugs with the biological systems that contribute to their absorption, distribution, metabolism, elimination and toxicity (ADME-T).
For this, the lab has expertise in the formulation of drugs and the preparation of drug carriers on one hand, and profound knowledge of biological systems involved on the other hand.
The group focuses on the understanding on complex drugs of biological and non-biological origin, nanomedicines and vaccines by using physico-chemical characterization.
We develop in vitro models representing tissues involved in their absorption, metabolism and immune response.
We strive to optimize the interaction between complex drugs and biological systems in terms of an enhanced efficacy and safety.
With regard to the technological part, we are engaged in the development of new formulations and vectors for complex drug application in a targeted and individualized manner.
Such vectors are based on the synthesis of novel (bio) polymers functionalized with targeting moieties such as peptides, antibody fragments, and aptamers.
From a therapeutic point of view, one focus is on vaccination against infectious diseases. Formulations have been developed for pandemic vaccines, and a recent emphasis was put on Dengue fever.
New approaches for cancer (immuno)therapy are also investigated, such as the activation of STING pathway to boost anti-tumour immunity, or the design of new ligands for cancer nanomedicine.
Additional research related to osteoarthritis and vascular therapies is also performed.
Finally, our technical knowledge and scientific expertise allow us to be involved in discussions on complex medicines with regulatory authorities and pharmacopoeias.
